The effect of bisphosphonates on bone mineral density in metastatic prostate cancer patients who are treated with anti-androgen drugs and radiotherapy
| dc.contributor.author | Karaköse A. | |
| dc.contributor.author | Yüksel M.B. | |
| dc.contributor.author | Aydoʇdu Ö. | |
| dc.contributor.author | Gümüş B. | |
| dc.contributor.author | Ateşçi Y.Z. | |
| dc.contributor.author | Akan Z. | |
| dc.date.accessioned | 2025-04-10T11:11:02Z | |
| dc.date.available | 2025-04-10T11:11:02Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | Objective: To evaluate the potential effect of bisphosphonates on bone mineral density (BMD) in patients who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer.; Materials and Methods: The data of 31 patients with metastatic prostate cancer who were treated with anti-androgen drugs and radiotherapy during a 1-year period were retrospectively reviewed. Patients were divided in 2 groups, in which 17 patients in group 1 were treated with zoledronic acid (4 mg/month, intravenous) and 14 patients in group 2 who did not receive zoledronic acid. BMD was measured before the treatment and at the end of the 1st year by dual energy X-ray absorptiometry. Statistical analyses were performed with the T test.; Results: Mean age of the patients was 71.42 ± 6.7(range 59-85) years. A significant increase was noted for pelvic bone, femoral neck, and lumbar vertebrae t scores when pretreatment and 1st year measurements were compared in group 1 (p < 0.05). In group 2 a significant decrease was noted for pelvic bone and femoral neck t scores at the end of the 1st year (p < 0.05). A significant increase was noted for pelvic bone and femoral neck follow-up in BMD values at the end of the 1st year compared to initial measurements in group 1. A significant decrease was noted for lumbar vertebrae follow-up in BMD values at the end of the 1st year when compared to initial values in group 2.; Conclusion: Zoledronic acid significantly increases BMD and delays unfavorable outcomes for bones in men who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer. Copyright © 2013 S. Karger AG, Basel. | |
| dc.identifier.DOI-ID | 10.1159/000365672 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/49400 | |
| dc.publisher | S. Karger AG | |
| dc.title | The effect of bisphosphonates on bone mineral density in metastatic prostate cancer patients who are treated with anti-androgen drugs and radiotherapy | |
| dc.type | Article |